Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Badger Meter Inc (BMI) Price & Performance

Ascendis Pharma A/STrade
Badger Meter IncTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Badger Meter Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Badger Meter Inc trades at $135.56 (market cap $3.95B). The key difference: Ascendis Pharma A/S is far larger — about 4.2× Badger Meter Inc's market cap, and Badger Meter Inc pays a 1.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDBMI
Market Cap
$16.78B$3.95B
Sector
HealthTechnology
52-Week High
$277.18$193.09
52-Week Low
$189.74$113.41
Enterprise Value
$17.15B$3.86B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Badger Meter Inc

Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.

The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Badger Meter Inc

Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.

Read more on BMI